Primary membranous nephropathy
Conditions
Interventions
evolocumab:evolocumab
statin:statins
Sponsors
Department of Nephrology, Shandong Provincial Hospital affiliated to Shandong First Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 18 to 75 years of age 2. After listening to the explanation of the study and having the opportunity to ask questions, the subjects voluntarily signed an informed consent form approved by the ethics committee. 3. Renal biopsy-proven primary membranous nephropathy 4. Hypercholesterolemia
Exclusion criteria
Exclusion criteria: 1. positive for either HIV, HBs Ag, or anti-HCV Ab 2. chronic liver disease 3. malignant tumor history 4. complicated with autoimmune diseases, such as SLE, Sjogren's syndrome, antiphospholipid syndrome. 5. history of diabetes 6. history of coronary heart disease 7. history of venous system diseases such as varicose veins of lower extremity varicose veins or phlebitis 8. history of coagulation related diseases 9. acute or chronic infection, trauma, or operation. 10. Pregnant and lactant women 11. Application of estrogen and progesterone within 12 weeks before screening 12. Application of corticosteroids and immunosuppressive therapy within 12 weeks before screening 13. Application of statins within 12 weeks before screening 14. Application of PCSK9 inhibitors within 12 weeks before screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma tissue factor;plasma factor VIII activity; | — |
Secondary
| Measure | Time frame |
|---|---|
| prothrombin time;activated partial thromboplastin time;Antithrombin III;protein C;plasma PCSK9;Low-Density Lipoprotein Cholesterol;24 hour proteinuria; | — |
Countries
China
Contacts
Public ContactRong Wang
Shandong Provincial Hospital affiliated to Shandong First Medical University
Outcome results
None listed